Yes, I think our management has executed brilliantly in terms of establishing commercialization and distribution infrastructure. The fact that CYFY management seems to have not expressed much interest in fulfilling this EUA requirement, leads me to suspect that their focus is concentrated on a successful trial result, for the most part. Perhaps this is what a potential tender offer is waiting on.
Like for lenzilumab, lero also has applications to the treatment of other indications. And I agree, they are likely going to need more revenue than can be generated with the small and decreasing Covid patient population they are targeting.
I'm a fan of what you bring to the discussion on this board, Corundum. I'm glad you're here.
News 
Market Data 
Discover 
